Incyte Corporation has launched a new drug known as Jakafi which is recently approved from Food and Drug Administration (FDA). It is beneficial for the treatment of patient suffering from Polycythemia Vera and also suffering from inter mediate or high risk myelofibrosis. These myelofibros is include primary myelofibrosis (MF), past Polycythemia Vera MF & post essential thrombocythemia MF.
In Myelofibrosis , Fibrosis occurs in bone marrow. Its is almost a rare condition or the replace ment of bone marrow by collagenous connective tissue fibres. Myelotibrisis is a form of myeloid metaplasia & often the two terms are used synonymously.